Fisetin and quercetin: what does senolytic mean?

Longevity circles have a word for everything, and "senolytic" is the one that sounds like a sci-fi villain with a good lab budget. Fisetin and quercetin keep turning up next to it, usually with the word "zombie" attached. It's a fun idea, and the research behind it is genuinely interesting. Let's work out what the word means, what has been tested in mice and in people, and why these two compounds are two different stories.

A senolytic is a compound that selectively kills senescent cells: damaged cells that have stopped dividing but linger in tissue. The idea is well supported in mice. People are a different story. The first human senolytic trials are tiny and early, and most used a prescription cancer drug (dasatinib) together with quercetin, not quercetin alone. Fisetin has promising mouse data and a handful of small completed human trials, mostly in other conditions and with mixed results; none shows that it clears senescent cells, and the Mayo trials built around that question haven't reported yet. Quercetin has its own, separate evidence for blood pressure. So neither compound has yet been shown, in healthy people, to do what the word "senolytic" describes.

Zombie cells: what senescence is, and why anyone would want to remove it

When a cell is stressed or damaged beyond repair, one option is senescence: it stops dividing and stays put. That is useful. Baker and colleagues note in their 2016 paper that senescence prevents damaged cells from multiplying and has beneficial roles in tissue remodelling during development and wound healing. The suspected problem is accumulation. Senescent cells build up in tissues with age, and they release inflammatory and tissue-remodelling signals known as the senescence-associated secretory phenotype, or SASP. Cellular senescence is one of the twelve hallmarks of ageing in a widely cited 2023 framework (López-Otín and colleagues), which lists it alongside genomic instability, mitochondrial dysfunction, chronic inflammation and others.

The "does removing them help?" experiments were done in mice, and they are the reason the field exists:

• In 2011, Baker and colleagues built a transgene (INK-ATTAC) that lets researchers eliminate p16-positive senescent cells with a drug. In fast-ageing mice, removing those cells delayed age-related changes in fat, muscle and eye, and removal late in life slowed the progress of disorders that had already started.
• In 2016, the same approach starting at one year of age extended median lifespan in normal mice of two genetic backgrounds, delayed tumours and slowed deterioration of the kidney, heart and fat tissue.

Those experiments used a genetic trick, not a capsule. They support the idea that senescent cells contribute to ageing in mice; what a pill can do in a person is a separate question.

How a compound earns the word "senolytic"

A senolytic is a drug or compound that kills senescent cells selectively, while leaving ordinary dividing cells mostly alone. The field's starting point is Zhu and colleagues' 2015 paper. The researchers found that senescent cells ramp up pro-survival networks to resist cell death, and that drugs hitting those networks could selectively remove them. Their first pair was dasatinib plus quercetin (D+Q). In the lab, dasatinib eliminated senescent human fat-cell progenitors, while quercetin was more effective against senescent human endothelial cells and mouse bone-marrow stem cells. In old mice, one dose improved cardiac function within five days.

Then came Xu and colleagues in 2018: intermittent oral D+Q in naturally aged mice relieved physical dysfunction and increased post-treatment survival by 36%, reducing the mortality hazard to 65%.

The key phrase is "hit-and-run". Senolytics are given in short, intermittent courses rather than daily, because the aim is to eliminate cells, not to keep a signal turned down. That logic is where the pulsed dosing protocols you see online come from; they get their own section below.

Two things to hold on to for the rest of the article:

1. "Senolytic" describes a mechanism, and it has to be shown separately for each compound, in each tissue, in each species.
2. In D+Q, the two ingredients do different jobs in different cell types. You cannot read the quercetin half as a stand-in for the whole combination.

Fisetin: strong in mice, still waiting in people

Fisetin is a flavonoid found in small amounts in fruit and vegetables.

The plain-language version. In a cell screen of ten flavonoids, fisetin was the most potent; in mice it reduced senescence markers. In people, a handful of small trials have tested it for bone turnover, knee osteoarthritis, Gulf War Illness, carpal tunnel syndrome and COVID-19. Results were mixed or inconclusive, and none of them was designed to show that fisetin clears senescent cells. The trials built around that question, run by Mayo Clinic, are still going. Fisetin also seems hard to get into the blood, so what a trial finds for one formulation can't simply be carried over to another. The detail behind each point follows, as a reference layer.

Fisetin research detail

Mouse and cell evidence. Yousefzadeh and colleagues (2018) screened ten flavonoids for senolytic activity in senescent mouse and human fibroblasts. Fisetin was the most potent. In progeroid (fast-ageing) mice and in old wild-type mice, short or intermittent treatment reduced senescence markers in multiple tissues, consistent with a hit-and-run mechanism. Fisetin reduced senescence in a subset of cells in mouse and human fat tissue, which shows it does not hit every cell type. Given late in life to wild-type mice, it reduced age-related pathology and extended median and maximum lifespan.

Human evidence. In short: a few small trials, mixed, and not the ones that matter most. A 2026 review in Nutrients searched the trial registries and found 34 registered fisetin trials, of which four were completed with results available. Its verdict: clinical evidence remains limited and heterogeneous, with some studies reporting favourable changes in metabolic or inflammatory outcomes and others finding no clear benefit, in small, multi-part or exploratory designs. The four are summarised below from their ClinicalTrials.gov records (read 8 October 2026):

• Trial: NCT04313634, Mayo Clinic; Who and what: Women aged 60 or over; 20 weeks; not blinded; fisetin vs dasatinib plus quercetin vs no treatment; 74 enrolled, with 14 in the fisetin group (11 in the main analysis); What the registry and review show: Primary outcome was a bone-breakdown marker (CTX). The fisetin group's median change was a rise of 13.7%, against a fall of 7.7% in untreated women; the registry posts no statistical test for fisetin. The review calls the fisetin result inconclusive because of the small numbers. Investigator-sponsored.
• Trial: NCT04210986, Steadman Philippon Research Institute; Who and what: Adults aged 40 to 80 with knee osteoarthritis; randomised, double-blind, placebo-controlled; 34 on fisetin, 40 on placebo; What the registry and review show: Primary outcome was safety: 28 of 34 on fisetin and 33 of 40 on placebo had at least one adverse event. Inflammation markers, cartilage markers and walking distance showed no clear difference; the review says there was no consistent benefit. Listed collaborators include the US Department of Defense and the Office of Naval Research.
• Trial: NCT02909686, University of Alabama at Birmingham; Who and what: Gulf War Illness; 36 people tried nine botanical supplements, fisetin among them, in a crossover design with placebo; What the registry and review show: Fisetin did not significantly improve symptom severity compared with placebo; the review notes few participants had evaluable fisetin data. A US Department of Defense research programme (Congressionally Directed Medical Research Programs) is listed as a collaborator.
• Trial: NCT05416515, Mayo Clinic; Who and what: 40 adults with carpal tunnel syndrome; everyone received fisetin, with no placebo or control group; What the registry and review show: The registry reports a mean change of -0.5 points on a 1-to-5 symptom questionnaire (higher means worse), but without a comparison group the change can't be put down to fisetin, as the review points out. Investigator-sponsored.

A fifth completed trial isn't in that review, which excluded COVID-19 studies. COVFIS-HOME (NCT04771611) was a randomised, double-blind, placebo-controlled Mayo Clinic pilot in 55 adults with COVID-19 (29 on fisetin, 26 on placebo). Its results are posted on the registry; a search on 8 October 2026 found no peer-reviewed paper. At 60 days, 26 of 27 evaluable people on fisetin and 22 of 24 on placebo scored as having no activity limitation; serious adverse events were 0 on fisetin and 2 on placebo. It was a pilot run by its sponsor-investigator, and it says nothing about senescent cells or ageing.

Put together, that is a handful of small, mostly exploratory trials with mixed or inconclusive results, none designed to show that fisetin clears senescent cells in healthy people. The trials built around that question are still running. The review also notes a preliminary vascular-function result from the Colorado trial below that has so far appeared only as a conference abstract.

Registered trials that haven't reported are plans, not findings. This is what the registry showed on 8 October 2026 for the senescence-focused ones:

• Trial: NCT03675724, Mayo Clinic, adults aged 70 or over; Design as registered: Phase 2, randomised, double-blind; intermittent high-dose fisetin vs placebo; about 40 people; primary outcome blood inflammation markers; Status on the registry: Enrolling by invitation; estimated primary completion November 2026, completion November 2027; no results posted
• Trial: NCT03430037, Mayo Clinic, women aged 70 or over; Design as registered: Same pulsed approach, repeated over two months; about 40 people; primary outcome 6-minute walk; Status on the registry: Enrolling by invitation; estimated primary completion November 2026, completion November 2027; no results posted
• Trial: NCT06133634, University of Colorado Boulder; Design as registered: Fisetin and vascular function in older adults; about 70 people; Status on the registry: Active, not recruiting; no results posted on the registry
• Trial: NCT07195318, Hvidovre University Hospital (Denmark), investigator Ove Andersen; Design as registered: Daily 100 mg for 7 weeks in adults aged 50 or over, as in the published protocol; about 120 people; primary outcome an inflammation marker (suPAR); Status on the registry: Recruiting; no results posted

The Danish trial's daily low dose and the Mayo trials' short, high-dose pulses are two quite different ways of testing the same compound, which shows that nobody has settled how fisetin should be tested, let alone taken.

For scale, the Mayo pulse dose of 20 mg/kg for a 70 kg adult works out at 1.4 g in a day (our arithmetic, to give a sense of size rather than a dose). It is a trial dose given under supervision, not a recommendation.

Absorption. Fisetin seems hard to get into the blood. In a single-dose crossover study of 15 healthy volunteers, 1,000 mg of unformulated fisetin produced a peak plasma level of about 10 ng/ml, while a proprietary fenugreek-fibre hydrogel formulation, delivering 192 mg of fisetin, produced a peak more than 23 times higher. The authors work for the ingredient maker and a supplement company (Akay Natural Ingredients and Life Extension), and the study measured blood levels, not senescent cells or health outcomes. It does show that format matters, and that data on one formulation can't be borrowed for another.

Quercetin: two separate stories under one name

Quercetin is a flavonol found across fruit and vegetables (a 2019 review of dietary quercetin and kaempferol covers the food sources), and it is also sold as a supplement. Unlike fisetin, it has a long history of human trials for outcomes other than senescence.

The plain-language version. The senolytic studies in people didn't test quercetin alone. They tested it alongside dasatinib, a prescription cancer medicine, and that combination is a different thing from a quercetin capsule. Of the four studies below, Hickson 2019 is the one that looked directly at senescent-cell markers (in biopsies from nine people), and it had no control group. The larger body of human evidence for quercetin on its own is about blood pressure, where pooled trials show small average falls. That says nothing about senescent cells. As with fisetin, the detail follows as a reference layer.

Quercetin research detail

Senolytic evidence in people. All the human senolytic work below used quercetin together with dasatinib, which is a prescription-only cancer medicine (the European Medicines Agency's Sprycel page lists it for certain leukaemias: chronic myeloid leukaemia and Philadelphia-chromosome-positive acute lymphoblastic leukaemia). This is a drug-plus-supplement combination used in supervised research, not a supplement regimen.

• Study: Justice 2019; Who and what: 14 people with idiopathic pulmonary fibrosis; open-label; D 100 mg + Q 1,250 mg daily, three days a week for three weeks; What it found: Primary aim was feasibility: all 14 stayed in the study. Walking distance, gait speed and chair-stand time improved, but there was no control group. One serious adverse event; non-serious events included respiratory symptoms, skin irritation or bruising and gastrointestinal discomfort.
• Study: Hickson 2019; Who and what: 9 people with diabetic kidney disease; open-label; D 100 mg + Q 1,000 mg for three days; What it found: Fat-tissue and skin senescent cell markers and several circulating SASP factors were lower 11 days after treatment, compared with before. Small, uncontrolled, with biopsies as the evidence.
• Study: Gonzales 2023; Who and what: 5 people with early Alzheimer's disease; open-label; 12 weeks; What it found: Well tolerated; cognitive and imaging measures did not significantly change. Dasatinib was detected in cerebrospinal fluid in four of five; quercetin was not detected.
• Study: Farr 2024; Who and what: 60 postmenopausal women; randomised, controlled; intermittent D+Q; What it found: Primary endpoint (a bone resorption marker) did not differ from control. A bone formation marker rose about 16% at two and four weeks, but not at 20 weeks. Benefit in a subgroup with higher senescent cell burden came from exploratory analysis. No serious adverse events.

Read together: D+Q has been tested in humans, safely enough that trials go on, and with signals that need confirming in larger controlled studies. Nothing here shows that quercetin on its own clears senescent cells in people, and no trial of that kind turned up in an 8 October 2026 search. The Alzheimer's study shows why the two halves can't be swapped: the quercetin was not found in the fluid around the brain.

Quercetin on its own: other outcomes. The most developed human evidence concerns blood pressure. Three meta-analyses of randomised trials are broadly consistent:

• Serban 2016: 7 trials, 587 people. Systolic pressure fell by about 3 mmHg (WMD -3.04) and diastolic by about 2.6 mmHg; the effect may be limited to, or larger at, doses above 500 mg/day.
• Huang 2020: 17 trials, 896 people. Systolic -3.09 mmHg and diastolic -2.86 mmHg; no significant change in lipids or glucose overall.
• Popiolek-Kalisz 2022: 10 trials, 841 people. Systolic -2.38 mmHg in the mixed population.

These are small average changes in trials that varied in design. They are evidence about blood pressure, and say nothing about senolysis.

Absorption. Quercetin is absorbed and then quickly converted: it circulates mainly as glucuronide, methyl and sulphate conjugates, and a 2018 review found substantial variation in absorption between individuals. Another review notes that foods with the most quercetin are not always the most bioavailable, and that the glucoside form in onions appears to be well absorbed. Enhanced formats (phytosome, liposomal and so on) exist, but the sources behind this page contain no human data for specific products, and a higher blood level is not a senolytic outcome.

Safety. A safety review of isolated quercetin supplements (Andres and colleagues, 2018) found that adverse effects in human studies were rarely reported and mild. It also found no adequate data on long-term use (over 12 weeks) of high doses of 1,000 mg or more per day, and that animal studies flagged possible concerns about quercetin enhancing nephrotoxic effects in already damaged kidneys and promoting tumour development in oestrogen-dependent cancers. It reported that animal and human studies found interactions with certain drugs. People with kidney disease, hormone-sensitive conditions or regular medication should talk to a doctor or pharmacist first; our guide to supplement and drug interactions is a good starting point for that conversation.

Fisetin and quercetin side by side

• : Strongest evidence; Fisetin: Mouse and cell studies; most potent of ten flavonoids tested in a cell screen; Quercetin: Human trials for blood pressure; mouse and cell evidence as a senolytic
• : Human senolytic data; Fisetin: None yet: a few small completed trials in other conditions with mixed results, and the senescence-focused trials still running; Quercetin: Only with dasatinib, in small open-label studies and one controlled bone trial
• : Human outcome trials; Fisetin: Mostly registered; four small completed trials with posted results (plus a COVID-19 pilot), none conclusive; Quercetin: Many, with meta-analyses for blood pressure, lipids and glucose
• : Main open questions; Fisetin: Does it reach tissues in people? Does it clear senescent cells and does that help?; Quercetin: Does quercetin alone do anything senolytic in people?
• : Safety data; Fisetin: Little published on repeated dosing; Quercetin: Reviewed; rare, mild adverse effects at studied doses; gaps for long-term high doses; drug interactions

Pulse dosing: a trial design, not a standard

You may meet monthly "pulse" protocols with two or three consecutive high-dose days. They come from the hit-and-run logic and from trial designs like those above, and they are experimental. The human trials that used them were small, run under medical supervision, mostly used dasatinib alongside quercetin, and were testing feasibility or particular conditions. No result shows that a fisetin or quercetin capsule schedule clears senescent cells or slows ageing in healthy people, so we aren't giving a schedule: no evidence-based one exists.

EU and Dutch status

We couldn't confirm the EU novel-food status of fisetin or quercetin, so we make no statement about it. Check the Commission's Novel Food Status Catalogue before buying, and check current official guidance for what a Dutch supplement may contain. Dasatinib is a prescription-only cancer medicine (the EMA lists it for certain leukaemias), not a supplement ingredient.

What to watch while the trials report

"Senolytic" is both a serious research idea and a lively marketing word. The animal evidence is promising, the human trials are tiny and mostly involve a cancer drug, and the fisetin trials aimed at senescence are still to report. Quercetin has a separate, more ordinary track record for blood pressure. If the idea has caught your imagination, the registered trials are the thing to follow: the Mayo fisetin results, when they arrive, will say more than any product page can.

If you're comparing products, our guide to reading supplement labels covers serving sizes, forms and what "standardised" does and doesn't tell you.

Where to read next

Senolytics is one longevity idea among several. These guides cover the others and the bigger picture.

• Longevity: mechanisms versus human outcomes, for how to read a longevity label as a description of a mechanism rather than an outcome.
• Resveratrol: the ingredient behind the headlines, for where the headlines came from and what mice and people actually showed.
• Spermidine: why the longevity interest?, for the autophagy story, what food studies and supplement trials found, and the EU rules.
• NMN and NAD: understand the relationship, for how NAD+, NMN, NR and niacin relate and what human trials found.

Written by Smart Supplements with AI assistance from the sources linked in the text. It has not been reviewed by a clinician.

Last updated: 12 October 2026

This article is for informational purposes only and is not intended as medical advice. Always consult a healthcare professional before starting any new supplement, especially if you take prescription medication.